Can Fite Biopharma

CANFPhase 3

Can Fite Biopharma focuses on the discovery and clinical development of platform-based therapeutics that engage the A3 adenosine receptor, a target highly expressed in inflammatory and cancer cells. Its most advanced programs, Piclidenoson and Namodenoson, are in Phase 3 and Phase 2b trials, respectively, for major autoimmune diseases and liver cancer. The company's strategy involves advancing its clinical pipeline through partnerships and its public listing, aiming to bring novel, orally administered treatments to market.

Market Cap

$6.7M

Employees

11-50

Focus

Biotech

CANF · Stock Price

USD 3.17236.83 (-98.68%)

Historical price data

AI Company Overview

Technology Platform

Platform of orally bioavailable small molecule drugs that target the A3 Adenosine Receptor (A3AR), which is overexpressed in inflammatory and cancer cells, to induce apoptosis and modulate inflammation.

Pipeline Snapshot

22 drugs in pipeline, 6 in Phase 3

Drug	Indication	Stage
CF101 2mg + CF101 3mg + Apremilast 30mg + Placebo Oral Tablet	Plaque Psoriasis	Phase 3
piclidenoson + Placebo	Plaque Psoriasis	Phase 3
CF101	Keratoconjunctivitis Sicca	Phase 3
CF101 1 mg + CF101 2 mg + Placebo + MTX	Rheumatoid Arthritis	Phase 3
Namodenoson + Placebo	Hepatocellular Carcinoma	Phase 3

Funding History

Total raised: $23.5M

PIPE$7.5MUndisclosedDec 15, 2021

PIPE$5MUndisclosedSep 15, 2019

IPO$8MUndisclosedFeb 11, 2015

Seed$3MUndisclosedJun 15, 2010

Opportunities

Significant opportunities exist in the large, underserved NASH market and the difficult-to-treat Child-Pugh B hepatocellular carcinoma population.

Success in ongoing trials could lead to lucrative partnership deals.

The oral administration of its drugs provides a key competitive and commercial advantage in crowded therapeutic areas.

Risk Factors

High clinical trial failure risk, as evidenced by the Phase 3 psoriasis trial missing its primary endpoint.

Persistent financial risk due to reliance on dilutive equity financing to fund operations.

Intense competition from large pharma companies with deep pockets and established products in target markets.

Competitive Landscape

Faces intense competition from dominant biologic and oral therapies in autoimmune diseases (e.g., AbbVie, Johnson & Johnson, Novartis) and from targeted therapies and immunotherapies in liver cancer (e.g., Roche, Bayer, Eisai). Can Fite's differentiation is based on its novel A3AR mechanism, oral dosing, and targeted safety profile, particularly in niche patient populations where other treatments are not suitable.